Rx0000097 |
Valeant Pharmaceuticals North America, LLC |
03/31/2019 |
00187006410 |
ATIVAN® Tablets 1mg 1,000s |
01/18/2019 |
1830.35 |
32336.16 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The NDC# for this product changed on 02/03/2014. The product was not acquired within the last 5 years |
Rx0000097 |
Valeant Pharmaceuticals North America, LLC |
03/31/2019 |
00187006301 |
ATIVAN® Tablets .5mg 100s |
01/18/2019 |
139.90 |
2471.60 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The NDC# for this product changed on 02/03/2014. The product was not acquired within the last 5 years |
Rx0000097 |
Valeant Pharmaceuticals North America, LLC |
03/31/2019 |
00187006401 |
ATIVAN® Tablets 1mg 100s |
01/18/2019 |
186.89 |
3301.70 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
Rx0000097 |
Valeant Pharmaceuticals North America, LLC |
03/31/2019 |
00187006501 |
ATIVAN® Tablets 2mg 100s |
01/18/2019 |
297.84 |
5261.87 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The NDC# for this product changed on 12/12/2013. The product was not acquired within the last 5 years. |
Rx0000097 |
Valeant Pharmaceuticals North America, LLC |
03/31/2019 |
00187510001 |
ELIDEL® (pimecrolimus) Cream 1% |
01/18/2019 |
16.93 |
299.05 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
Rx0000097 |
Valeant Pharmaceuticals North America, LLC |
03/31/2019 |
00187510102 |
ELIDEL® (pimecrolimus) Cream 1% |
01/18/2019 |
33.86 |
598.11 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
Rx0000097 |
Valeant Pharmaceuticals North America, LLC |
03/31/2019 |
00187510203 |
ELIDEL® (pimecrolimus) Cream 1% |
01/18/2019 |
56.42 |
996.83 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
Rx0000097 |
Valeant Pharmaceuticals North America, LLC |
03/31/2019 |
00187305050 |
ONEXTON™ (Clindamycin Phosphate and Benzoyl Peroxide) Gel, 1.2%/3.75% |
01/18/2019 |
31.65 |
559.16 |
08/05/2029 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
Rx0000097 |
Valeant Pharmaceuticals North America, LLC |
03/31/2019 |
00187149825 |
TIMOPTIC® in OCUDOSE® (TIMOLOL MALEATE OPHTHALMIC SOLUTION) 0.25%, 0.3mL |
01/18/2019 |
23.68 |
418.27 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
11/06/2015 |
Aton Pharma, Inc. |
None |
1 |
None |
332.12 |
None |
2009 |
87.08 |
None |
1.The product was introduced to the market before acquisition by Valeant Pharmaceuticals North America LLC. (VPNA). The year of introduction and WAC at introduction contained in this report is the only information available to VPNA. VPNA has no knowledge of the actual date of introduction nor the WAC at introduction.
2. In regards to the 5 yr. WAN history the product was acquired on 11/06/2015. The information related to WAC history before that day is from publicly available sources and VPNA is unable to verify the accuracy of that information.
3. The NDC# for this product changed on 11/06/2015 |
Rx0000097 |
Valeant Pharmaceuticals North America, LLC |
03/31/2019 |
00187149605 |
TIMOPTIC® in OCUDOSE® (TIMOLOL MALEATE OPHTHALMIC SOLUTION) 0.50%, 0.3mL |
01/18/2019 |
27.00 |
476.97 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
08/09/2015 |
Aton Pharma, Inc. |
None |
1 |
None |
378.73 |
None |
2009 |
104.84 |
None |
1.The product was introduced to the market before acquisition by Valeant Pharmaceuticals North America LLC. (VPNA). The year of introduction and WAC at introduction contained in this report is the only information available to VPNA. VPNA has no knowledge of the actual date of introduction nor the WAC at introduction.
2. In regards to the 5 yr. WAN history the product was acquired on 08/09/2015. The information related to WAC history before that day is from publicly available sources and VPNA is unable to verify the accuracy of that information. |
Rx0000097 |
Valeant Pharmaceuticals North America, LLC |
03/31/2019 |
00187099445 |
ZOVIRAX® Cream 5gm |
01/18/2019 |
47.79 |
844.29 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
Rx0000097 |
Valeant Pharmaceuticals North America, LLC |
03/31/2019 |
00187099395 |
ZOVIRAX® Ointment 30gm |
01/18/2019 |
82.81 |
1463.00 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The product was not acquired within the last 5 years. |
Rx0000210 |
Validus Pharmaceuticals |
03/31/2019 |
30698041912 |
Equetro® (extended release carbamazepine capsules - bottle of 120) 100mg |
01/02/2019 |
40.21 |
463.46 |
05/19/2024 |
Single Source Drug |
3482 |
None |
API cost increase, Shipping cost increase, Manufacturer cost increases |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000210 |
Validus Pharmaceuticals |
03/31/2019 |
30698042312 |
Equetro® (extended release carbamazepine capsules - bottle of 120)300mg |
01/02/2019 |
50.92 |
586.87 |
05/19/2024 |
Single Source Drug |
6660 |
None |
API cost increase, Shipping cost increase, Manufacturer cost increases |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000210 |
Validus Pharmaceuticals |
03/31/2019 |
30698042112 |
Equetro®(extended release carbamazepine capsules - bottle of 120) 200mg |
01/02/2019 |
45.33 |
522.53 |
05/19/2024 |
Single Source Drug |
13051 |
None |
API cost increase, Shipping cost increase, Manufacturer cost increases |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000210 |
Validus Pharmaceuticals |
06/30/2019 |
30698006701 |
Lasix 20mg Tablet 100 count (Bottle of 100) |
04/01/2019 |
6.79 |
78.29 |
None |
Non-innovator Multiple Source Drug |
13327 |
None |
API cost increase, Shipping cost increase, Manufacturer cost increases |
None |
N/A |
None |
12/10/2015 |
Sanofi |
25000000 |
None |
purchased as a part of a portfolio from Sanofi, so the 25M acquisition price included a variety of products. |
59.63 |
59.63 |
2016 |
59.63 |
None |
None |
Rx0000210 |
Validus Pharmaceuticals |
06/30/2019 |
30698006605 |
Lasix 80mg Tablet 50 count (Bottle of 50) |
04/01/2019 |
7.70 |
88.70 |
None |
Non-innovator Multiple Source Drug |
4684 |
None |
API cost increase, Shipping cost increase, Manufacturer cost increases |
None |
N/A |
None |
12/10/2015 |
Sanofi |
25000000 |
None |
purchased as a part of a portfolio from Sanofi, so the 25M acquisition price included a variety of products. |
67.57 |
67.57 |
2016 |
67.57 |
None |
None |
Rx0000210 |
Validus Pharmaceuticals |
06/30/2019 |
30698006001 |
Lasix40mg Tablet 100 count (Bottle of 100) |
04/01/2019 |
9.52 |
109.72 |
None |
Non-innovator Multiple Source Drug |
21301 |
None |
API cost increase, Shipping cost increase, Manufacturer cost increases |
None |
N/A |
None |
12/10/2015 |
Sanofi |
25000000 |
None |
purchased as a part of a portfolio from Sanofi, so the 25M acquisition price included a variety of products. |
83.56 |
83.56 |
2016 |
83.56 |
None |
None |
Rx0000210 |
Validus Pharmaceuticals |
06/30/2019 |
30698045801 |
Lopressor 50mg tablets (Bottle of 100) |
04/01/2019 |
21.87 |
252.07 |
None |
Non-innovator Multiple Source Drug |
5209 |
None |
API cost increase, Shipping cost increase, Manufacturer cost increases |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Column 14 - 22 have been left blank as this product was acquired more than 5 years ago. |
Rx0000210 |
Validus Pharmaceuticals |
06/30/2019 |
30698045901 |
Lopressor100mg tablets (Bottle of 100) |
04/01/2019 |
32.69 |
376.79 |
None |
Non-innovator Multiple Source Drug |
824 |
None |
API cost increase, Shipping cost increase, Manufacturer cost increases |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Column 14 - 22 have been left blank as this product was acquired more than 5 years ago. |
Rx0000210 |
Validus Pharmaceuticals |
06/30/2019 |
30698045201 |
Lotensin HCT 10/12.5 Tablet (Bottle of 100) |
04/01/2019 |
23.12 |
266.52 |
None |
Non-innovator Multiple Source Drug |
83 |
None |
API cost increase, Shipping cost increase, Manufacturer cost increases |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Column 14 - 22 have been left blank as this product was acquired more than 5 years ago. |
Rx0000210 |
Validus Pharmaceuticals |
06/30/2019 |
30698045301 |
Lotensin HCT 20/12.5 Tablet (Bottle of 100) |
04/01/2019 |
23.12 |
266.52 |
None |
Non-innovator Multiple Source Drug |
335 |
None |
API cost increase, Shipping cost increase, Manufacturer cost increases |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Column 14 - 22 have been left blank as this product was acquired more than 5 years ago. |
Rx0000210 |
Validus Pharmaceuticals |
06/30/2019 |
30698045401 |
Lotensin HCT 20/25 Tablet (Bottle of 100) |
04/01/2019 |
23.12 |
266.52 |
None |
Non-innovator Multiple Source Drug |
1168 |
None |
API cost increase, Shipping cost increase, Manufacturer cost increases |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Column 14 - 22 have been left blank as this product was acquired more than 5 years ago. |
Rx0000098 |
Vanda Pharmaceuticals Inc. |
03/31/2019 |
43068010102 |
Fanapt 1 mg tablets; bottles of 60 |
01/01/2019 |
87.19 |
1177.10 |
12/28/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000098 |
Vanda Pharmaceuticals Inc. |
03/31/2019 |
43068011002 |
Fanapt 10 mg tablets; bottles of 60 |
01/01/2019 |
171.81 |
2319.45 |
12/28/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000098 |
Vanda Pharmaceuticals Inc. |
03/31/2019 |
43068011202 |
Fanapt 12 mg tablets; bottles of 60 |
01/01/2019 |
171.81 |
2319.45 |
12/28/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000098 |
Vanda Pharmaceuticals Inc. |
03/31/2019 |
43068010202 |
Fanapt 2 mg tablets; bottles of 60 |
01/01/2019 |
87.19 |
1177.10 |
12/28/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000098 |
Vanda Pharmaceuticals Inc. |
03/31/2019 |
43068010402 |
Fanapt 4 mg tablets; bottles of 60 |
01/01/2019 |
87.19 |
1177.10 |
12/28/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000098 |
Vanda Pharmaceuticals Inc. |
03/31/2019 |
43068010602 |
Fanapt 6 mg tablets; bottles of 60 |
01/01/2019 |
107.28 |
1448.34 |
12/28/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000098 |
Vanda Pharmaceuticals Inc. |
03/31/2019 |
43068010802 |
Fanapt 8 mg tablets; bottles of 60 |
01/01/2019 |
107.28 |
1448.34 |
12/28/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000098 |
Vanda Pharmaceuticals Inc. |
03/31/2019 |
43068011304 |
Fanapt 8 tablet titration pack |
01/01/2019 |
11.62 |
156.95 |
12/28/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000098 |
Vanda Pharmaceuticals Inc. |
03/31/2019 |
43068022001 |
Hetlioz; 20 mg capsules; bottles of 30 |
01/01/2019 |
1163.06 |
15701.35 |
02/12/2035 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000066 |
ViiV Healthcare |
03/31/2019 |
49702022318 |
SELZENTRY TAB 150MG |
01/01/2019 |
45.33 |
1556.20 |
11/25/2022 |
Single Source Drug |
None |
1 |
None |
1 |
The price increase listed are not related to any identified or claimed change or improvement. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Patent Expiration Date: Pursuant to Sec. 96070(d), if the drug is under patent, the patent expiration date is provided. The date provided is the latest expiration date of all patents listed with the USFDA under 21 CFR 314.53.
Note on Acquisition Fields: This drug was developed by ViiV Healthcare, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
Rx0000066 |
ViiV Healthcare |
03/31/2019 |
49702022418 |
SELZENTRY TAB 300MG |
01/01/2019 |
45.33 |
1556.20 |
11/25/2022 |
Single Source Drug |
None |
1 |
None |
1 |
The price increase listed are not related to any identified or claimed change or improvement. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Patent Expiration Date: Pursuant to Sec. 96070(d), if the drug is under patent, the patent expiration date is provided. The date provided is the latest expiration date of all patents listed with the USFDA under 21 CFR 314.53.
Note on Acquisition Fields: This drug was developed by ViiV Healthcare, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
Rx0000066 |
ViiV Healthcare |
03/31/2019 |
49702022613 |
TIVICAY TAB 10MG |
01/01/2019 |
16.58 |
348.10 |
12/08/2029 |
Single Source Drug |
None |
1 |
None |
1 |
The price increase listed are not related to any identified or claimed change or improvement. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Patent Expiration Date: Pursuant to Sec. 96070(d), if the drug is under patent, the patent expiration date is provided. The date provided is the latest expiration date of all patents listed with the USFDA under 21 CFR 314.53.
Note on Acquisition Fields: This drug was developed by ViiV Healthcare, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
Rx0000066 |
ViiV Healthcare |
03/31/2019 |
49702022713 |
TIVICAY TAB 25MG |
01/01/2019 |
41.44 |
870.25 |
12/08/2029 |
Single Source Drug |
None |
1 |
None |
1 |
The price increase listed are not related to any identified or claimed change or improvement. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Patent Expiration Date: Pursuant to Sec. 96070(d), if the drug is under patent, the patent expiration date is provided. The date provided is the latest expiration date of all patents listed with the USFDA under 21 CFR 314.53.
Note on Acquisition Fields: This drug was developed by ViiV Healthcare, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
Rx0000066 |
ViiV Healthcare |
03/31/2019 |
49702022813 |
TIVICAY TAB 50MG |
01/01/2019 |
82.88 |
1740.49 |
12/08/2029 |
Single Source Drug |
None |
1 |
None |
1 |
The price increase listed are not related to any identified or claimed change or improvement. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Patent Expiration Date: Pursuant to Sec. 96070(d), if the drug is under patent, the patent expiration date is provided. The date provided is the latest expiration date of all patents listed with the USFDA under 21 CFR 314.53.
Note on Acquisition Fields: This drug was developed by ViiV Healthcare, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |
Rx0000066 |
ViiV Healthcare |
03/31/2019 |
49702023113 |
TRIUMEQ TAB |
01/01/2019 |
84.16 |
2889.36 |
12/08/2029 |
Single Source Drug |
None |
1 |
None |
1 |
The price increase listed are not related to any identified or claimed change or improvement. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Note on Patent Expiration Date: Pursuant to Sec. 96070(d), if the drug is under patent, the patent expiration date is provided. The date provided is the latest expiration date of all patents listed with the USFDA under 21 CFR 314.53.
Note on Acquisition Fields: This drug was developed by ViiV Healthcare, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION. |